TOP2A Gene Status in HER2+ Breast Cancer

Tumor biopsies of 18 patients with HER2 positive breast cancer were collected in our previous neoadjuvant study as published [6 (link)]. They consisted of eight HER2 and ten luminal-HER2 cases that were collected from patients after neoadjuvant treatment with four cycles of epirubicin (E, 90 mg/m2) and cyclophosphamide (C, 600 mg/m2), every 3 weeks prior to surgery. Pretreatment biopsies were also collected and stored as either formalin-fixed or paraffin embedded blocks. The study was approved by the Yokohama City University Medical Center in 2006.
The TOP2A gene status was examined by fluorescence in-situ hybridization (FISH) (TOP2A FISH pharmDx^™ Kit; DAKO) in pre-treatment tumor biopsies. TOP2A copy number was then determined in a minimum of 20 interphase, non-overlapping, tumor cell nuclei and compared with that of chromosome 17 centromeres (CEP17) in the same nuclei. The ratio of TOP2A to CEP17 signals was then calculated. In accordance with previous reports, a TOP2A/CEP17 ratio greater than 2.0 was defined as gene amplification [4 (link), 5 (link)].

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Ishikawa T., Sasaki T., Tanabe M., Narui K., Kida K., Shimada K., Shimizu D., Yamada A., Morita S., Oba M.S., Kawachi K., Nozawa A., Ichikawa Y., Takabe K, & Endo I. (2014). The Pathological Response to Anthracycline is Associated with Topoisomerase IIα Gene Amplification in the HER2 Breast Cancer Subset. Journal of surgery and science, 2(1), 10-12.

Publication 2014

TOP2A FISH pharmDx™ Kit

After treatment Biopsies Breast cancer Centromeres Chromosome 17 Cyclophosphamide Epirubicin Fluorescence in situ hybridization Formalin Gene Gene amplification Her2 Interphase Luminal Neoadjuvant Nuclei Paraffin Patients Surgery Top2a Tumor

Corresponding Organization :

Other organizations : Tokyo Medical University, Yokohama City University Medical Center, Yokohama City University

Top 5 similar protocols

Variable analysis

independent variables

Neoadjuvant treatment with four cycles of epirubicin (E, 90 mg/m2) and cyclophosphamide (C, 600 mg/m2), every 3 weeks prior to surgery

dependent variables

TOP2A gene status examined by fluorescence in-situ hybridization (FISH) in pre-treatment tumor biopsies
TOP2A copy number determined in a minimum of 20 interphase, non-overlapping, tumor cell nuclei and compared with that of chromosome 17 centromeres (CEP17) in the same nuclei
Ratio of TOP2A to CEP17 signals calculated

control variables

Pretreatment biopsies collected and stored as either formalin-fixed or paraffin embedded blocks

controls

No positive or negative controls were explicitly mentioned in the provided information.

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!